{"protocolSection": {"identificationModule": {"nctId": "NCT00498433", "orgStudyIdInfo": {"id": "CSPP100A2238"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension", "officialTitle": "Part 1: An Open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin- Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity"}, "statusModule": {"statusVerifiedDate": "2014-09", "overallStatus": "TERMINATED", "whyStopped": "Early termination resulted from interim analysis of the ALTITUDE trial", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-06"}, "primaryCompletionDateStruct": {"date": "2012-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-07-08", "studyFirstSubmitQcDate": "2007-07-08", "studyFirstPostDateStruct": {"date": "2007-07-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-03-21", "resultsFirstSubmitQcDate": "2013-10-23", "resultsFirstPostDateStruct": {"date": "2013-10-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-09-09", "lastUpdatePostDateStruct": {"date": "2014-09-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal muscle tissues (biopsies); aliskiren, amlodipine and angiotensin II concentrations, and renin activity and concentration in plasma.\n\nPart 2 investigated the potential for aliskiren to modulate renin-angiotensin-aldosterone system (RAAS) activity, and lipid/carbohydrate metabolism in adipose and skeletal muscle tissue in obese patients with hypertension in comparison to amlodipine."}, "conditionsModule": {"conditions": ["Hypertension", "Abdominal Obesity"], "keywords": ["Aliskiren", "Renin-Angiotensin System (RAS)", "Hypertension", "Abdominal obesity"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 46, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren", "type": "EXPERIMENTAL", "description": "Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..\n\nPart 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks.", "interventionNames": ["Drug: Aliskiren", "Drug: Placebo of Aliskiren", "Drug: Placebo of amlodipine"]}, {"label": "Amlodipine", "type": "ACTIVE_COMPARATOR", "description": "Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be \u2264 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.\n\nPart 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks", "interventionNames": ["Drug: Amlodipine", "Drug: Placebo of Aliskiren"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "300 mg tablet once daily", "armGroupLabels": ["Aliskiren"], "otherNames": ["SPP100"]}, {"type": "DRUG", "name": "Amlodipine", "description": "5 mg capsule once daily", "armGroupLabels": ["Amlodipine"]}, {"type": "DRUG", "name": "Placebo of Aliskiren", "description": "Matching placebo of aliskiren 300 mg tablet", "armGroupLabels": ["Aliskiren", "Amlodipine"]}, {"type": "DRUG", "name": "Placebo of amlodipine", "description": "Matching placebo of amlodipine 5 mg capsule", "armGroupLabels": ["Aliskiren"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Part 1: Aliskiren Concentrations From Interstitial Fluid (Microdialysis)at the End of Aliskiren Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentrations on the last day of the aliskiren treatment periods (Day 42).", "timeFrame": "Day 42"}, {"measure": "Part 1: Amlodipine Concentrations From Interstitial Fluid (Microdialysis) at the End of Amlodipine Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentration on the last day of the amlodipine treatment periods (Day 98).", "timeFrame": "Day 98"}, {"measure": "Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Aliskiren Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "timeFrame": "Day 42"}, {"measure": "Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Amlodipine Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "timeFrame": "Day 98"}, {"measure": "Part 1: Aliskiren Concentrations From Tissue at the End of Aliskiren Treatment Period", "description": "Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine aliskiren concentration. Tissue biopsy samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42).", "timeFrame": "Day 42"}, {"measure": "Part 1: Angiotensin II Levels From Tissue During Aliskiren Treatment Period", "description": "Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine Ang II concentration.", "timeFrame": "Day 42"}, {"measure": "Part 1: Renin Activity and Concentrations From Adipose and Skeletal Tissues During Aliskiren Treatment Period", "timeFrame": "Day 42"}, {"measure": "Part 1: Aliskiren Concentrations From Plasma at the End of Aliskiren Treatment Period", "description": "Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42).", "timeFrame": "Day 42"}, {"measure": "Part 1: Amlodipine Concentrations From Plasma at the End of Amlodipine Treatment Period", "description": "Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the amlodipine treatment periods (Day 98).", "timeFrame": "Day 98"}, {"measure": "Part 1: Angiotensin II Levels in Plasma During Aliskiren Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "timeFrame": "Day 42"}, {"measure": "Part 1: Angiotensin II Levels in Plasma During Amlodipine Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "timeFrame": "Day 98"}, {"measure": "Part 1: Renin Concentrations From Plasma During Aliskiren Treatment Period", "description": "Renin concentrations from plasma were measured as: plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration).", "timeFrame": "Day 42"}, {"measure": "Part 1: Renin Concentrations From Plasma During Amlodipine Treatment Period", "description": "Renin concentrations from plasma were measured as plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration).", "timeFrame": "Day 98"}, {"measure": "Part 1: Renin Activity From Plasma During Aliskiren Treatment Period", "description": "Plasma Renin activity (PRC) was measured by a trapping PRA (tPRA) assay.", "timeFrame": "Day 42"}, {"measure": "Part 1: Renin Activity From Plasma During Amlodipine Treatment Period", "description": "Plasma renin activity (PRC) was measured by a trapping PRA (tPRA) assay.", "timeFrame": "Day 98"}, {"measure": "Part 2: Change From Baseline in Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Double Blind Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)"}, {"measure": "Part 2: Change From Baseline in Plasma Angiotensin II Levels During Double Blind Treatment Period", "description": "Plasma Ang II was measured prior to and 1 hour after the Insulin modified-frequently sampled intravenous glucose tolerance test (IM-FSIGT) during placebo treatment (Days 14) and active treatment(Day 98).", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)"}, {"measure": "Part 2: Plasma Renin Activity (PRA) Concentration During Double Blind Treatment Period", "timeFrame": "Day 98"}, {"measure": "Part 2: Plasma Renin Concentration (PRC) Levels During Double Blind Treatment Period", "timeFrame": "Day 98"}], "secondaryOutcomes": [{"measure": "Part 2: Microdialysis Metabolic Analytes in Response to Insulin Modified Frequently Sampled Intravenous Glucose Test [IM-FSIGT]for Each Tissue (Adipose or Skeletal Muscle)", "timeFrame": "Day 14 and Day 98"}, {"measure": "Part 2: Change From Baseline in Official Blood Pressure", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)"}, {"measure": "Part 2: Renin Activity and Concentration of Aliskiren and Amlodipine in Fat and Skeletal Muscle Interstitial Fluid", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)"}, {"measure": "Part 2: Change From Baseline in Peripheral Insulin Sensitivity in Response to Insulin Modified Frequently Sampled Intravenous Glucose Test [IM-FSIGT]for Each Tissue (Adipose or Skeletal Muscle)", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)"}, {"measure": "Part 2: Change From Baseline in Mitochondrial Mass in Subcutaneous Fat and Skeletal Muscle (Tissue Biopsies)", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)"}, {"measure": "Part 2: Number of Participants With Reported Any Adverse Events, Serious Adverse Events and Death", "timeFrame": "98 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\nPART 1:\n\n* Male and female patients 20 to 65 years of age with a diagnosis of hypertension and with abdominal obesity (waist circumference \u2265 102 cm in men and \u2265 88 cm in women)\n* For patients with a history of treated hypertension, mean sitting systolic blood pressure (msSBP)/ mean sitting diastolic blood pressure (msDBP) had to be \u2265 120/80 mmHg and \u2264 160/100 mm Hg. For patients with newly diagnosed, untreated hypertension msSBP/msDBP had to be \u2265 135/85 mmHg and \u2264 160/100 mm Hg\n* Pulse rate 40 - 90 bpm\n\nPART 2:\n\n* Male and female patients 18 to 65 years of age , with a diagnosis of hypertension and with abdominal obesity (waist circumference \u2265 102 cm in men and \u2265 88 cm in women)\n* Systolic and diastolic blood pressure and pulse rate were assessed after the patient had rested for at least five (5) minutes. Vital signs had to be within the following ranges:\n\n  1. Patients with history of treated hypertension: msSBP/msDBP \u2265 135/85 mmHg and \\< 160/100 mmHg at baseline\n  2. Patients with newly diagnosed, untreated hypertension: msSBP/msDBP \u2265 135/85 mmHg and \\< 160/100 mmHg at screening and baseline.\n\nExclusion criteria:\n\nPART 1\n\n* Hypertension Grade 2 (msSBP \u2265 160 mmHg) or Grade 3 (msDBP \u2265 110 mmHg and/or msSBP \u2265 180 mmHg) WHO classification\n* Current treatment with three or more antihypertensive drugs.\n\nPART 2\n\n* Hypertension Grade 2 (msSBP \u2265 160 and/or msDBP \u2265 100 mmHg).\n* Current treatment with three or more antihypertensive drugs.\n\nOther protocol-defined inclusion/exclusion criteria applied", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Investigative site", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Berlin-Buch", "zip": "13125", "country": "Germany"}, {"facility": "Novartis Investigative Site", "city": "Hannover", "zip": "30159", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Total 46 patients entered into the study; 10 patients in part 1 received study drug. 36 patients enrolled into part 2 and and 16 patients received study drug.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 2, Period 1: After confirming study eligibility based on inclusion and exclusion criteria, patients underwent a two week single-blind placebo run-in phase."}, {"id": "FG001", "title": "Aliskiren", "description": "Part 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "FG002", "title": "Amlodipine", "description": "Part 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.\n\nPart 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "periods": [{"title": "Part 1, Period 1:Placebo Run-in(2 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Part 1, Period 2: Aliskiren (4 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Part 1, Period 3: Amlodipine (4-8 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Part 2: Placebo Run-in (2 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "comment": "For part 2, this arm belongs to randomized, double blind period.", "numSubjects": "0"}, {"groupId": "FG002", "comment": "For part 2, this arm belongs to randomized, double blind period.", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Abnormal laboratory value", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Abnormal test procedure", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Part 2: Double Blind (12 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Part 1 : Baseline measures are on all patients.\n\nPart 2: Randomized population of double-blind period used for Baseline/Demographic measurements.", "groups": [{"id": "BG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}, {"id": "BG001", "title": "Part 2, Double Blind Period: Aliskiren", "description": "Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "BG002", "title": "Part 2, Double Blind: Amlodipine", "description": "Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "26"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "Part 1, Open Label", "categories": [{"measurements": [{"groupId": "BG000", "value": "46", "spread": "7.5"}, {"groupId": "BG001", "value": "NA", "spread": "NA", "comment": "This arm is used for part 2, double blind period"}, {"groupId": "BG002", "value": "NA", "spread": "NA", "comment": "This arm is used for part 2, double blind period"}, {"groupId": "BG003", "value": "46", "spread": "7.5"}]}]}, {"title": "Part 2, Double blind", "categories": [{"measurements": [{"groupId": "BG000", "value": "NA", "spread": "NA", "comment": "This arm is used for part 1, open label ."}, {"groupId": "BG001", "value": "46.0", "spread": "10.92"}, {"groupId": "BG002", "value": "49.4", "spread": "10.53"}, {"groupId": "BG003", "value": "47.7", "spread": "10.17"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "20"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Part 1: Aliskiren Concentrations From Interstitial Fluid (Microdialysis)at the End of Aliskiren Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentrations on the last day of the aliskiren treatment periods (Day 42).", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacokinetics (PK)/ pharmacodynamics (PD) data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Adipose tissue", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.38", "spread": "2.11"}]}]}, {"title": "Skeletal muscle", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.05", "spread": "4.24"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Amlodipine Concentrations From Interstitial Fluid (Microdialysis) at the End of Amlodipine Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method. Interstitial fluid was collected for measurements of drug concentration on the last day of the amlodipine treatment periods (Day 98).", "populationDescription": "Zero flow concentrations from microdialysates could not be derived by linear regression because of missing data due to inadequate sample volumes.", "reportingStatus": "POSTED", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Part 2: Microdialysis Metabolic Analytes in Response to Insulin Modified Frequently Sampled Intravenous Glucose Test [IM-FSIGT]for Each Tissue (Adipose or Skeletal Muscle)", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Day 14 and Day 98", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Part 2: Change From Baseline in Official Blood Pressure", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Part 2: Renin Activity and Concentration of Aliskiren and Amlodipine in Fat and Skeletal Muscle Interstitial Fluid", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Aliskiren Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "populationDescription": "Due to technical limitations, zero flow concentrations could not be derived for Ang II.", "reportingStatus": "POSTED", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 1: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Amlodipine Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "populationDescription": "Due to technical limitations, zero flow concentrations could not be derived for Ang II.", "reportingStatus": "POSTED", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 1: Aliskiren Concentrations From Tissue at the End of Aliskiren Treatment Period", "description": "Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine aliskiren concentration. Tissue biopsy samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42).", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacokinetics data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/g", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"title": "Adipose tissue (n=6)", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.05", "spread": "16.71"}]}]}, {"title": "Skeletal muscle (n=9)", "categories": [{"measurements": [{"groupId": "OG000", "value": "107.32", "spread": "68.64"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Angiotensin II Levels From Tissue During Aliskiren Treatment Period", "description": "Biopsies were taken from abdominal adipose and skeletal muscle tissue to determine Ang II concentration.", "populationDescription": "More than 50% of the biopsy samples over all time points were either below lower limit of quantification (LLOQ) or not received.", "reportingStatus": "POSTED", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 1: Renin Activity and Concentrations From Adipose and Skeletal Tissues During Aliskiren Treatment Period", "populationDescription": "Renin activity and concentration from adipose tissue and skeletal muscles were all below lower limitation of quantification (LLOQ) at all time points.", "reportingStatus": "POSTED", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 1: Aliskiren Concentrations From Plasma at the End of Aliskiren Treatment Period", "description": "Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the aliskiren treatment periods (Day 42).", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacokinetics data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.38", "spread": "4.41"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Amlodipine Concentrations From Plasma at the End of Amlodipine Treatment Period", "description": "Plasma samples were obtained for measurement of aliskiren or amlodipine concentrations. All blood samples were taken by an indwelling cannula inserted in a forearm vein or direct venipuncture. The plasma samples for drug concentrations analyses were taken on the last day of the amlodipine treatment periods (Day 98).", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacokinetics data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.78", "spread": "3.61"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Angiotensin II Levels in Plasma During Aliskiren Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacodynamic data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "fmol/mL", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.534", "lowerLimit": "0.223", "upperLimit": "1.28"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Angiotensin II Levels in Plasma During Amlodipine Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacodynamic data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "fmol/mL", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.20", "lowerLimit": "0.88", "upperLimit": "5.51"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Renin Concentrations From Plasma During Aliskiren Treatment Period", "description": "Renin concentrations from plasma were measured as: plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration).", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacodynamic data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Plasma Renin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.29", "lowerLimit": "8.98", "upperLimit": "55.32"}]}]}, {"title": "Total Renin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.9", "lowerLimit": "52.4", "upperLimit": "154.2"}]}]}, {"title": "Prorenin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "62.1", "lowerLimit": "40.2", "upperLimit": "96.0"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Renin Concentrations From Plasma During Amlodipine Treatment Period", "description": "Renin concentrations from plasma were measured as plasma renin concentration (PRC), prorenin concentration and total renin concentration (renin + prorenin concentration).", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacodynamic data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"title": "Plasma Renin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.36", "lowerLimit": "4.24", "upperLimit": "12.80"}]}]}, {"title": "Total Renin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.3", "lowerLimit": "49.8", "upperLimit": "88.2"}]}]}, {"title": "Prorenin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "57.9", "lowerLimit": "44.1", "upperLimit": "76.1"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Renin Activity From Plasma During Aliskiren Treatment Period", "description": "Plasma Renin activity (PRC) was measured by a trapping PRA (tPRA) assay.", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacodynamic data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/nl/h", "timeFrame": "Day 42", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.145", "lowerLimit": "0.055", "upperLimit": "0.386"}]}]}]}, {"type": "PRIMARY", "title": "Part 1: Renin Activity From Plasma During Amlodipine Treatment Period", "description": "Plasma renin activity (PRC) was measured by a trapping PRA (tPRA) assay.", "populationDescription": "All patients who received at least one dose of study drug and had at least one post-baseline assessment of pharmacodynamic data were included in the data analysis.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ng/nl/h", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Part 1: Placebo/Aliskiren/Amlodipine", "description": "Part 1, Period 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase.\n\nPart 1 , Period 2: All eligible patients received 4 week treatment of 300 mg aliskiren o.d..\n\nPart 1, Period 3: All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.670", "lowerLimit": "0.269", "upperLimit": "1.672"}]}]}]}, {"type": "PRIMARY", "title": "Part 2: Change From Baseline in Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle (Microdialysis) During Double Blind Treatment Period", "description": "Interstitial fluid was obtained from subcutaneous adipose and skeletal muscle tissues by microdialysis using the zero-flow method to determine Ang II concentration.", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 2: Change From Baseline in Plasma Angiotensin II Levels During Double Blind Treatment Period", "description": "Plasma Ang II was measured prior to and 1 hour after the Insulin modified-frequently sampled intravenous glucose tolerance test (IM-FSIGT) during placebo treatment (Days 14) and active treatment(Day 98).", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 2: Plasma Renin Activity (PRA) Concentration During Double Blind Treatment Period", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients of this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients of this arm received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Part 2: Plasma Renin Concentration (PRC) Levels During Double Blind Treatment Period", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Day 98", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Part 2: Change From Baseline in Peripheral Insulin Sensitivity in Response to Insulin Modified Frequently Sampled Intravenous Glucose Test [IM-FSIGT]for Each Tissue (Adipose or Skeletal Muscle)", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Part 2: Change From Baseline in Mitochondrial Mass in Subcutaneous Fat and Skeletal Muscle (Tissue Biopsies)", "populationDescription": "Total 40 completed subjects needed to have a power of 80% in detecting a significant difference between treatment groups. Due to early termination, the study was limited by a small sample size; hence, the planned analysis was not done.", "reportingStatus": "POSTED", "timeFrame": "Placebo Baseline (Day 14), Active Treatment (Day 98)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Part 2, Double Blind Period: Eligible randomized patients received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Part 2: Number of Participants With Reported Any Adverse Events, Serious Adverse Events and Death", "populationDescription": "The safety population consisted of all patients who received at least one dose of study drug with at least one post-baseline safety assessment. Patients were analyzed according to treatment received.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "98 days", "groups": [{"id": "OG000", "title": "Placebo run-in", "description": "Part 2, Period 1, Placebo run-in phase: After confirming study eligibility based on inclusion and exclusion criteria, patients will undergo a two week single-blind placebo run-in phase."}, {"id": "OG001", "title": "Aliskiren", "description": "Part 2, Double Blind Period: Eligible randomized patients of this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks"}, {"id": "OG002", "title": "Amlodipine", "description": "Part 2, Double Blind: Eligible randomized patients of this arm received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Serious Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "The Safety Population consisted of all patients that received at least one dose of study drug with at least one post-baseline safety assessment.\n\nIn Part 1 of the study, no events were reported in period 1 when patients received placebo.", "eventGroups": [{"id": "EG000", "title": "Part 1: Aliskiren", "description": "All eligible patients received 4 week treatment of 300 mg aliskiren o.d..", "seriousNumAffected": 1, "seriousNumAtRisk": 10, "otherNumAffected": 6, "otherNumAtRisk": 10}, {"id": "EG001", "title": "Part 1: Amlodipine", "description": "All patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 3, "otherNumAtRisk": 10}, {"id": "EG002", "title": "Part 2: Placebo run-in Period", "description": "After confirming study eligibility based on inclusion and exclusion criteria, patients will undergo a two week single-blind placebo run-in phase.", "seriousNumAffected": 1, "seriousNumAtRisk": 36, "otherNumAffected": 1, "otherNumAtRisk": 36}, {"id": "EG003", "title": "Part 2: Aliskiren", "description": "Eligible randomized patients of this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 2, "otherNumAtRisk": 8}, {"id": "EG004", "title": "Part 2: Amlodipine", "description": "Double Blind Period: Eligible randomized patients of this arm received amlodipine 5 mg o.d. and aliskiren placebo o.d. for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 3, "otherNumAtRisk": 8}], "seriousEvents": [{"term": "MUSCLE HAEMORRHAGE", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "HYPERTENSIVE CRISIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}], "otherEvents": [{"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}]}, {"term": "DRY MOUTH", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "IRRITABILITY", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "RHINITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "CONTUSION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}]}, {"term": "MUSCLE STRAIN", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "POST PROCEDURAL HAEMATOMA", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "WEIGHT INCREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "PARAESTHESIA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "INSOMNIA", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "DYSURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}]}, {"term": "ERECTILE DYSFUNCTION", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "COUGH", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 8}]}, {"term": "PSORIASIS", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 10}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 8}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000009765", "term": "Obesity"}, {"id": "D000056128", "term": "Obesity, Abdominal"}], "ancestors": [{"id": "D000050177", "term": "Overweight"}, {"id": "D000044343", "term": "Overnutrition"}, {"id": "D000009748", "term": "Nutrition Disorders"}, {"id": "D000001835", "term": "Body Weight"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "asFound": "Obesity", "relevance": "HIGH"}, {"id": "M28427", "name": "Obesity, Abdominal", "asFound": "Abdominal Obesity", "relevance": "HIGH"}, {"id": "M26186", "name": "Overweight", "relevance": "LOW"}, {"id": "M25307", "name": "Overnutrition", "relevance": "LOW"}, {"id": "M12684", "name": "Nutrition Disorders", "relevance": "LOW"}, {"id": "M5114", "name": "Body Weight", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}